IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.099
AS - Asia 2.737
EU - Europa 1.765
SA - Sud America 427
AF - Africa 176
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.019
CN - Cina 1.017
SG - Singapore 681
IE - Irlanda 510
HK - Hong Kong 371
VN - Vietnam 341
BR - Brasile 321
RU - Federazione Russa 271
DE - Germania 210
FI - Finlandia 155
FR - Francia 142
ZA - Sudafrica 141
IT - Italia 136
GB - Regno Unito 88
IN - India 70
UA - Ucraina 60
AR - Argentina 42
CA - Canada 40
BD - Bangladesh 36
IQ - Iraq 29
MX - Messico 29
SE - Svezia 29
ES - Italia 26
PL - Polonia 26
JP - Giappone 24
TR - Turchia 23
AT - Austria 17
NL - Olanda 17
PK - Pakistan 17
BE - Belgio 15
CO - Colombia 15
SA - Arabia Saudita 15
ID - Indonesia 14
EC - Ecuador 13
LT - Lituania 11
VE - Venezuela 10
JO - Giordania 9
LB - Libano 9
PH - Filippine 9
UZ - Uzbekistan 9
MA - Marocco 8
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
CH - Svizzera 6
CL - Cile 6
EG - Egitto 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
BG - Bulgaria 5
KE - Kenya 5
PT - Portogallo 5
TH - Thailandia 5
IR - Iran 4
JM - Giamaica 4
KR - Corea 4
NO - Norvegia 4
AM - Armenia 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
PE - Perù 3
CY - Cipro 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
Totale 8.200
Salva come PNG Salva come JPEG
Città #
Dublin 510
Singapore 379
Hong Kong 360
Chandler 349
San Jose 344
Ashburn 319
Dallas 271
Beijing 242
Nanjing 158
Johannesburg 128
Los Angeles 108
Ho Chi Minh City 104
Lauterbourg 101
Boardman 99
Helsinki 96
Jacksonville 94
Hanoi 93
Princeton 73
Lawrence 68
New York 65
Munich 58
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Buffalo 50
Redondo Beach 49
Shanghai 48
Shenyang 42
São Paulo 42
Jiaxing 38
Orem 37
Moscow 36
Hebei 35
Changsha 34
Pavia 34
Hangzhou 31
Milan 25
Tianjin 24
Tokyo 23
Warsaw 23
Frankfurt am Main 22
Santa Clara 22
Council Bluffs 21
Da Nang 19
Denver 18
London 18
Nuremberg 18
The Dalles 18
Haiphong 17
Montreal 17
Poplar 16
Turku 16
Woodbridge 16
Brussels 15
Norwalk 15
Redwood City 15
Seattle 15
Atlanta 14
Chennai 14
Falkenstein 14
San Francisco 14
Mexico City 13
Brooklyn 12
Chicago 12
Ankara 11
Piscataway 11
Stockholm 11
Toronto 11
Baghdad 10
Amman 9
Amsterdam 9
Belo Horizonte 9
Fairfield 9
Hải Dương 9
Phoenix 9
Rio de Janeiro 9
Washington 9
Biên Hòa 8
Brasília 8
Riyadh 8
Beirut 7
Charlotte 7
City of London 7
Curitiba 7
Guangzhou 7
Houston 7
Hyderabad 7
Manchester 7
Vienna 7
Boston 6
Jeddah 6
Manaus 6
Montevideo 6
Paris 6
Rome 6
Tamm 6
Tashkent 6
Zhengzhou 6
Cape Town 5
Totale 5.468
Salva come PNG Salva come JPEG
Nome #
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 147
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 122
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 120
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 119
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 119
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 118
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 115
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 114
Bone marrow amyloidosis. 113
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 110
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 110
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 109
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 108
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 106
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 106
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 105
Prognostication of survival and progression to dialysis in AA amyloidosis 105
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 104
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 103
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 99
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 98
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 98
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 98
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 97
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 97
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 96
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 95
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
A case of monoclonal gammopathy of renal significance 91
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 90
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 90
Regulated expression of amyloidogenic immunoglobulin light chains in mice 89
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 89
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 88
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 86
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 83
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 83
Cystatin F is a biomarker of prion pathogenesis in mice 82
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 80
Development and Validation of Staging Systems for AA Amyloidosis 79
Cells and prions: A license to replicate 79
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 78
Prion protein and Ab-related synaptic toxicity impairment 77
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 77
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 76
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 75
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 75
A neuroprotective role for microglia in prion diseases 74
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 74
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 74
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 74
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 73
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 73
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 73
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 72
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 72
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 71
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 71
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 71
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 70
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 69
Structure-based drug design identifies polythiophenes as antiprion compounds 69
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 68
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 68
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 66
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 63
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 63
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 62
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 62
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 61
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 61
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 61
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 60
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 59
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 59
The workings of the amyloid diseases. 58
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 58
Systemic amyloidosis: novel therapies and role of biomarkers 57
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 56
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 54
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 54
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 53
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 53
The Priority position paper: Protecting Europe's food chain from prions 53
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 52
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 51
Author Correction: The dengue-specific immune response and antibody identification with machine learning 51
SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies 49
The immunobiology of prion diseases 49
Management of the elderly patient with AL amyloidosis 48
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 47
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 45
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 44
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis 44
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 44
Redirecting proteoxicity 43
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 43
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis 40
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 39
Totale 7.796
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 0 0 0 0 0 0 17 16 2
2021/2022280 3 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/20251.541 28 110 12 37 17 119 94 97 401 69 187 370
2025/20263.945 283 271 371 507 606 157 795 271 472 212 0 0
Totale 8.414